BioMarin

BioMarin is a prominent biopharmaceutical company founded in 1997, dedicated to developing and commercializing innovative therapies for patients with serious, life-threatening rare diseases. The company maintains a robust pipeline of genetic and metabolic treatments, focusing on high-unmet-need conditions. By leveraging advanced biotechnology, BioMarin delivers specialized enzyme replacement therapies and gene-based solutions that address complex medical challenges globally.

Operating with 1,000-5,000 employees, BioMarin manages a diverse portfolio including Vimizim, Naglazyme, Kuvan, Palynziq, Brineura, Voxzogo, and Aldurazyme. These products serve specialty pharmacies, hospitals, and government agencies across the United States, Europe, and Latin America. Learn about BioMarin's global headquarters for more information on their operational footprint and manufacturing capabilities. The company continues to pioneer advancements in rare disease research, maintaining a strong competitive presence against firms like Alexion and Biogen.

With annual revenue reaching $3.2B, BioMarin demonstrates significant market stability and growth within the pharmaceutical sector. The organization remains committed to equitable access and scientific discovery, supported by a global workforce. Explore financial highlights to review detailed performance metrics and funding history. Additionally, Meet BioMarin's team to understand the leadership driving their strategic commercialization and research initiatives. BioMarin’s commitment to rare disease patients remains the core driver of its long-term business strategy and ongoing clinical development efforts.